Detalles de la búsqueda
1.
Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions.
Eur J Haematol
; 111(4): 644-654, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37503797
2.
Carbon dioxide-mediated generation of hybrid nanoparticles for improved bioavailability of protein kinase inhibitors.
Pharm Res
; 31(3): 694-705, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23990314
3.
Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform.
Clin Pharmacol Drug Dev
; 2024 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38808617
4.
Matrix effects in nilotinib formulations with pH-responsive polymer produced by carbon dioxide-mediated precipitation.
Int J Pharm
; 494(1): 205-17, 2015 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26276256
5.
Physical characterization of anhydrous and hydrous forms of the hydrochloride salt of BVT.5182 a novel 5-HT(6) receptor antagonist.
Drug Dev Ind Pharm
; 32(2): 185-96, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16537199
6.
Diastereoselective reduction of a chiral N-Boc-protected delta-amino-alpha,beta-unsaturated gamma-keto ester Phe-Gly dipeptidomimetic.
J Org Chem
; 67(26): 9186-91, 2002 Dec 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-12492319
Resultados
1 -
6
de 6
1
Próxima >
>>